GC Cell said on Friday that it signed an agreement with IQVIA, the world's largest contract research organization (CRO), to conduct a multicountry phase 1 clinical trial of its CAR-NK cell therapy targeting solid tumors, AB201.Accordingly, GC Cell plans to conduct multicountry clinical trials of AB-
Seoul National University Bundang Hospital (SNUBH) announced that its researchers have secured 1.6 billion won ($1.18 million) in research funding for conducting clinical research using artificial intelligence (AI) to select the best embryos for implantation during in vitro fertilization (IVF).Profe
Despite Korea reducing Covid-19 emergency response levels, immunology experts elaborated that the only way to keep the virus under control was through seasonal updated vaccination to adapt to the mutating virus. In response, Moderna Korea held a press conference on Thursday to share data on the clin
GC Biopharma said on Thursday that its drug candidate to treat thrombotic thrombocytopenic purpura (GC1126A) has received orphan drug designation from the U.S. FDA on Sept. 27.Accordingly, the orphan drug designation will provide tax breaks on research and development expenses, exemption from permit
Lotte Biologics said on Wednesday that it signed a land purchase agreement with the Incheon Free Economic Zone Authority (IFEZ) to build three bioprocessing plants in Songdo, Incheon, by 2030.The plants will be situated at Songdo International Business District, Block KI20 in Zone 11, and will have
GSK Korea said on Wednesday that it appointed Maurizio Borgatta as its new general manager as of Oct. 1.Borgatta will fill the shoes of outgoing GSK Korea General Manager, Rob Kempton, who has led GSK Korea since 2020. Subsequently, Kempton will serve as Head of the Vaccines Market in Europe.Since j
Handok said on Wednesday that it entered into a strategic partnership with global biopharmaceutical company Sobi to strengthen its rare disease business. Sobi, a Swedish biopharmaceutical specializing in rare diseases, provides innovative therapies in hematology, immunology, and specialty care, with
Korean pharmaceutical companies are stepping up competition to develop microneedle patch-type obesity treatments, often called “adhesive obesity drugs.”Four companies -- Daewon Pharmaceutical, Dong-A ST, Kwangdong Pharmaceutical, and Daewoong Group – have joined the competition.According to industry
Celltrion said on Wednesday that it received approval from the FDA for its 80 mg and 20 mg dosage forms of Yuflyma, a biosimilar referencing Abbvie's Humira (ingredient: adalimumab), adding to the existing approval for the 40 mg dose. Humira, the original medicine, is prescribed primarily for autoim
Roche Korea said on Wednesday that its oral treatment for spinal muscular atrophy (SMA), Evrysdi (ingredient: risdiplam), obtained health insurance coverage from Oct.1.Accordingly, Evrysdi will be covered for patients with 5q SMA with a confirmed genetic diagnosis of a deletion or mutation in the 5q
Handok said on Wednesday that it submitted an IND plan for a global phase 2/3 clinical trial of HDB001A, a biliary tract cancer drug candidate, to the Ministry of Food and Drug Safety (MFDS). The global phase 2/3 study of HDB001A will enroll 150 patients at more than 35 sites in Korea and overseas.
Bridge Biotherapeutics announced on Tuesday that it will discontinue the development of BBT-176, a drug candidate for non-small cell lung cancer (NSCLC), and BBT-212, another candidate for fundus disease.Instead, the company stated it would focus on BBT-877 and BBT-207, candidates for idiopathic pul
Daewon Pharmaceutical said Monday the company has signed a contract with PT Interbat, an Indonesian pharmaceutical company, for the exclusive export and supply of finished products of non-steroidal anti-inflammatory drugs (NSAIDs), Pelubi SR Tab (pelubiprofen).The contract's total value is $3 millio
AbClon said Monday the company would expand its phase 2 clinical trial for its chimeric antigen receptor T-cell (CAR-T) therapy candidate, AT101. to seven sites.In addition to Asan Medical Center, Ajou University Hospital, Ulsan National University Hospital, and Dong-A University Hospital, where the
Dongkook Pharmaceutical is drawing the industry’s attention by completing the phase 3 clinical trial of its new therapy for benign prostatic hyperplasia (BPH), which combines dutasteride and tadalafil.Dongkook Pharm said Monday that it has confirmed the efficacy and safety of DKF-313, an improved co
Janssen, which will launch the first generic version of prostate cancer treatment Zytiga (abiraterone acetate) with insurance benefit, has introduced Akeega, a prostate cancer therapy combining the existing abiraterone and PARP inhibitor niraparib, in Korea.On Monday, the Ministry of Food and Drug S
Pinotbio, a local biotech specializing in antibody-drug conjugates (ADC), said it has been selected for a major ADC development project sponsored by the Korea Drug Development Fund (KDDF).The initiative, named the "Global Blockbuster ADC Anticancer Drug Component Development Project," aims to suppor
EyeGene said on Friday in a public filing that its phase 2 clinical trial of EG-Myocin, a drug candidate for the treatment of myocardial ischemia and reperfusion injury, failed to show statistically significant changes in myocardial infarction size. The study explored the effectiveness and safety of
Starting in October, the reimbursement standards for the spinal muscular atrophy (SMA) drugs Spinraza (nusinersen) and Evrysdi (risdiplam) will be expanded and newly established.The Ministry of Health and Welfare (MOHW) issued an administrative notice on the “Partial amendment to the details (pharma
Celltrion Healthcare said on Monday it won bids in major European countries for three of its anti-cancer biosimilars, Truxima (ingredient: rituximab), Herzuma (ingredient: trastuzumab), and Vegzelma (ingredient: bevacizumab), since switching to direct sales. On the same day, Celltrion also announced